Clinical trial
Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to…
NCT00180011 · DiMango, Emily, M.D., Other · Completed
Key facts
| NCT number | NCT00180011 |
|---|---|
| Title | Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma |
| Official title | Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma |
| Lead sponsor | DiMango, Emily, M.D., Other |
| Collaborators | Genentech, Inc. Industry Novartis |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Omalizumab |
| Enrollment | 18 |
| Start date | Sep 1, 2005 |
| Primary completion | Feb 1, 2012 |
| Completion | Feb 1, 2012 |
| First posted | Sep 16, 2005 |
| Last update posted | Feb 28, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: